Stock of the Day

December 7, 2023

Phio Pharmaceuticals (PHIO)

$1.09
-$0.04 (-3.5%)
Market Cap: $13.13M

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Today's Trend

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is receiving a potentially positive research and intellectual-property catalyst, although the company remains unprofitable and analyst estimates for 2026 were revised lower. The stock is trading near its 50-day moving average, with relatively light volume compared with its average.

  • The U.S. Patent and Trademark Office issued a notice of allowance for Phio’s patent application covering its INTASYL composition PH-894, which selectively targets the BRD4 protein. The allowance strengthens Phio’s intellectual-property position around a potential cancer-immunotherapy candidate, though the patent has not yet formally been issued. Phio Pharmaceuticals Secures U.S. Notice of Allowance
  • Sidoti significantly improved several 2027 projections, including raising its FY2027 EPS forecast to a loss of $0.45 from a loss of $0.91. Estimates for the first three quarters of 2027 and fourth-quarter 2027 were also improved, suggesting expectations for reduced losses over time. Phio Pharmaceuticals analyst estimates
  • Reported short-interest data was inconsistent: one update showed 287,349 shares sold short as of July 31, up 61.8% from mid-July, equal to about 2.5% of shares outstanding and only 0.9 days to cover; a later report listed zero short interest, likely reflecting a data or reporting issue. The relatively low days-to-cover figure suggests limited potential for a major short squeeze. Phio Pharmaceuticals short interest data
  • Sidoti lowered its FY2026 EPS forecast to a loss of $1.42 from $1.35 and cut its Q3 and Q4 2026 forecasts to losses of $0.35 and $0.37, respectively. This reinforces that Phio is expected to continue reporting substantial losses in the near term. Sidoti Phio Pharmaceuticals estimates
← Previous Stock of the DayNext Stock of the Day →